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360Recent Decrease in Acute Graft-versus-Host Disease in
Children with Leukemia Receiving Unrelated Donor
Bone Marrow Transplants
Stella M. Davies,1 DanWang,2 TaoWang,3 Muhkta Arora,2 Olle Ringden,4 Claudio Anasetti,5
Steven Pavletic,6 James Casper,7 Margaret L. MacMillan,8 Jean Sanders,9
Donna Wall,10 Nancy A. Kernan11Unrelated donor (URD) bone marrow transplantation (BMT) is an effective treatment for leukemia in
children, but its success is threatened by graft-versus-host disease (GVHD) and relapse. In this report, we
describe the incidence of and risk factors for GVHD over time in children receiving URD BMT. We analyzed
outcomes of 638 myeloablative URD BMTs performed between 1990 and 2003 to treat acute myelogenous
leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia, or myelodysplastic
syndrome MDS, using the Center for International Blood and Marrow Transplant Research (CIBMTR) data-
base. All recipients were under age 18 years and had available high-resolution HLA typing for HLA-A, -B, -C,
and -DRB1. Overall, 27% of the recipients developed acute GVHD (aGVHD) grade III-IV; the risk was
significantly higher in children receiving T cell–replete grafts compared with those receiving T cell–depleted
grafts (odds ratio [OR] 5 3.12; 95% confidence interval [CI] 5 2.02 to 4.83; P\ .0001). Acute GVHD
significantly reduced the risk of relapse in children with ALL (OR 5 0.34; 95% CI 5 0.13 to 0.86;
P 5 .0052), but not in those with AML (OR 5 0.58; 95% CI 5 0.22 to 2.98; P 5 .26). The risk of aGVHD
was higher in children undergoing transplantation in 1990-1998 (n 5 365) compared with those doing so
in 1999-2003 (OR 5 1.93; 95% CI 5 1.27 to 2.91; P 5 .002). We conclude that outcomes have changed
significantly over time, with a reduced risk of aGVHD associated with the more recent transplantations.
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6/j.bbmt.2008.12.495The early success of BMT in pediatric populations
allowed extension of the treatment to adult popula-
tions, and today, the majority of BMTs are performed
in adults.The distribution of diagnoses, comorbid con-
ditions, and the impact of previous treatments differ
significantly between pediatric and adult populations.
Most studies have found superior outcomes in younger
patient populations [4-8]; however, patient numbers
are generally too low to enable a detailed analysis of
the impact of younger age on specific outcomes.
The occurrence of graft-versus-host disease
(GVHD) significantly threatens the success of unrelated
donor (URD)BMTand is a frequent cause ofmorbidity
and mortality. In this study, we used a large Center for
International Blood and Marrow Transplant Research
(CIBMTR) database of myeloablative URD BMT
to perform a detailed analysis of risk factors for and
clinical impacts of acute GVHD (aGVHD) and chronic
GVHD (cGVHD) in a pediatric population. Our data
indicate some significant temporal changes in the
outcomes of URD BMT for children with leukemia.
In particular, the risk of aGVHD was higher in
children who underwent transplantation in 1990-1998
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risk of relapse was lower in the former group.PATIENTS AND METHODS
The CIBMTR
The CIBMTR, a research affiliation of the Interna-
tional Bone Marrow Transplant Registry (IBMTR),
Autologous Blood and Marrow Transplant Registry
(ABMTR), and the National Marrow Donor Program
(NMDP), is a voluntary working group comprising
more than 450 transplantation centers worldwide.
These centers contribute detailed data on consecutive
allogeneic and autologous hematopoietic stem cell
transplantations to a Statistical Center at the Health
Policy Institute of the Medical College of Wisconsin
in Milwaukee or the NMDP Coordinating Center in
Minneapolis. Participating centers are required to
report all transplantations consecutively; compliance is
monitored by onsite audits. Patients are followed longi-
tudinally, with yearly follow-up. Computerized checks
for errors, physicians’ review of submitted data, and on-
site audits of participating centers ensure data quality.
The CIBMTR collects data at 2 levels: registration
and research. Registration data include disease type,
age, sex, pretransplantation disease stage and chemo-
therapy responsiveness, date of diagnosis, graft type
(bone marrow– and/or blood-derived stem cells), con-
ditioning regimen, posttransplantation disease progres-
sion and survival, development of a new malignancy,
and cause of death. Requests for data on progression
or death for registered patients are made at 6-month in-
tervals. All CIBMTR teams contribute registration
data. Research data, including detailed disease, pre-
transplantation, and posttransplantation clinical infor-
mation, are collected on subsets of registered patients
selected using a weighted randomization scheme.
Patients and Transplantation Procedure
The analysis was restricted to BMT recipients
under age 18 years with available results of high-
resolution typing reported by the transplantation
center or performed retrospectively by the NMDP
[9,10]. All patients received URD bone marrow as
the primary stem cell source. Patients receiving
peripheral blood stem cell or cord blood grafts were
excluded, because the natural history of GVHD may
differ in these cases.
Study Population
The NMDP retrospectively obtained consent for
data submission and study participation from surviving
patients or parents/legal guardians for transplantations
that it facilitated in the United States before 2002.
Thereafter, informed consent was obtained prospec-
tively. TheNMDP’s Institutional ReviewBoard waivedconsent for patients who had died before consent was
solicited (transplantations facilitated before 2002), and
any nonconsenting surviving patients were excluded.
To overcome the bias associated with the inclusion of
a proportion of surviving patients (those consenting)
but all deceased recipients, and hence their overrepre-
sentation, a sample of deceased patients was selected
using a weighted randomized scheme that adjusted for
overrepresentationofdeceasedpatients in the consented
cohort [11]. This weighted randomized scheme was de-
veloped based on all survivors included in the NMDP
database. A logistic regression model was fit to identify
the factors that predicted whether or not a patient had
consented to the use of data collected by the NMDP.
This analysis found that the following factors were asso-
ciated with the likelihood of a patient consenting: age,
disease type, race, sex, cytomegalovirus serostatus, and
country of transplantation (United States vs non-United
States). Using estimated consenting probabilities from
this model based on the characteristics of dead patients,
the biased coinmethodof randomizationwasperformed
to determine which of the dead patients likely would
have consented to participate had they been alive.
Thus, this procedure includes the dead patients at the
sameprobability as the survivingpatientswhoconsented
to participate.
The NMDP facilitated a total of 2013 pediatric
BMTs between 1990 and 2003 in patients with acute
myelogenous leukemia (AML), acute lymphoblastic
leukemia (ALL), chronic myelogenous leukemia
(CML), or myelodysplastic syndrome (MDS) as their
first transplantation, with bone marrow as the stem
cell source. High-resolution HLA typing was available
for 1043 of these patients. Approximately 12% of
dead patients (n 5 123) were deleted by the weighted
randomized method. Patients who had more than 1
antigenmismatch (n5 208) or who received a nonmye-
loablative preparative regimen (n5 28) were excluded.
An additional 46 patients were subsequently excluded
because of the presence of more than 1 allele mismatch
(n 5 30) or missing information on aGVHD or
cGVHD (n 5 16). The final study population com-
prised 638 children.
Patient characteristics are summarized in Table 1.
Themost common diagnosis was ALL, and themedian
patient age was 10 years (range,\1 year to 17.9 years).
Median donor age was 36 years (range, 19 to 60 years).
The patients received a variety of preparative regi-
mens, as determined by the individual transplantation
centers. Most of the recipients (90%) received total
body irradiation (TBI; 550 to 1500 cGy); 10% received
chemotherapy alone. Chemotherapic drugs adminis-
tered as part of the preparative regimen included
cyclophosphamide, busulfan, cytosine arabinoside, eto-
poside, and thiotepa. GVHDprophylaxis varied among
transplantation centers. The graft was depleted of
T cells ex vivo (TCD) in 37% of cases; these children
Table 1. Characteristics of Patients Age < 18 Years Who
Underwent URD BMT after a Myeloblative Conditioning
Regimen Reported to the CIBMTR between 1990 and 2003
Characteristic
Number of patients 638
Age at transplantation, years, median (range) 10 (<1 to 17.9)
Age at transplantation, years, n (%)
< 5 151 (24)
6 to 10 183 (29)
11 to15 167 (26)
>15 137 (21)
Male sex, n (%) 365 (57)
Performance score, n (%)
< 90 111 (17)
90 to 100 513 (80)
Unknown 14 (2)
Disease, n (%)
AML 168 (26)
ALL 329 (52)
CML 75 (12)
MDS 66 (10)
Disease status at transplantation, n (%)*
Early 175 (27)
Intermediate 310 (49)
Advanced 128 (20)
Other† 25 (4)
Donor age, years, median (range) 36 (19 to 60)
Donor age, years, n (%)
18 to 30 169 (26)
31 to 40 240 (38)
41 to 60 229 (36)
Donor–-recipient sex match, n (%)
Male/ Male 230 (36)
Male/ Female 132 (21)
Female/ Male 135 (21)
Female/ Female 141 (22)
Donor–recipient CMV match, n (%)
D(2)/R(2) 277 (43)
D(2)/R(+) 136 (21)
D(+)/R(2) 125 (20)
D(+)/R(+) 88 (14)
Unknown 12 (2)
Donor pregnancy status, n (%)
Male donor 362 (57)
Female, no pregnancy 117 (18)
One or more pregnancies 153 (24)
Unknown 6 (1)
Conditioning regimen, n (%)
Cy + TBI ± other 543 (85)
TBI + other 29 (5)
Bu + Cy ± other 57 (9)
Bu ± other 9 (1)
GVHD prophylaxis, n (%)
T cell depletion 234 (37)
CSA + MTX ± other 338 (53)
CSA ± other 18 (3)
FK506 ± other 46 (7)
MTX ± other 1 (<1)
Missing 1 (<1)
HLA match, n (%)
Matched 296 (46)
Single allele mismatch 84 (13)
Single antigen mismatch 258 (40)
Follow-up of survivors, months, median (range) 87 (3 to 195)
Cy indicates cyclophosphamide; Bu, busulfan; CSA, cyclosporin A; MTX,
methotrexate.
*Risk groups are defined as early, including AML or ALL in CR1, CML in
CP1, or MDS with RA or RARS; intermediate, including AML or ALL in$
CR2, CML in accelerated phase or$CP2; or advanced, including AML or
ALL in relapse or PIF, CML in blast phase, andMDSwith RAEB-Tor IPSS-4.
†Other (n5 25) includes ALL, disease status before transplantation miss-
ing (n 5 1); MDS, not otherwise specified (n 5 3); chronic myelomono-
cytic leukemia (n5 3); and paroxysmal nocturnal hemoglobinuria (n5 1).
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neurin inhibitor, based on thedegree ofTcell depletion;
67% received a non–T cell–depleted graft along with
GVHD prophylaxis with cyclosporine A or tacrolimus.
Risk groups were defined as follows: early, including
AML or ALL in first complete remission (CR1), CML
in first chronic phase (CP1), and MDS with refractory
anemia (RA) or RAwith ringed sideroblasts (RARS); in-
termediate, includingAMLorALL in$CR2andCML
in accelerated phase or$CP2; and advanced, including
AML or ALL in relapse or primary induction failure
(PIF), CML in blast phase, and MDS with RA with ex-
cess blasts in transformation (RAEB-t) or international
prognostic scoring system (IPSS-4).
Donor Selection and Bone Marrow Processing
Donor characteristics are summarized in Table 1.
High-resolution typing at HLA-A, -B, -C, and -DRB1
was performed for all donor–recipient pairs [12]. Of
the recipients, 46% were matched with their recipient
at all 8 loci, 13% had a single allele mismatch, and 40%
had a single antigen mismatch.
Statistical Analysis
Univariate analysis of survival was calculated using
theKaplan-Meiermethod, and comparisonsweremade
using log-rank statistics [13,14]. Rates of aGVHD,
cGVHD, and relapse were calculated using cumulative
incidence,with death serving as the competing risk [15].
Cumulative incidences for aGVHD, cGVHD, and
relapse were compared using Taylor series linear ap-
proximation to estimate the variance [16].
The proportional hazards model was used for the
multivariate analysis of survival [17]. Cumulative inci-
dence estimates of aCVHD, cGVHD, relapse, and
treatment-related mortality (TRM) were estimated
using the pseudovalue approach of Klein [18]. Addi-
tional models were constructed for relapse and TRM,
treating aGVHD as a time-dependent variable. Vari-
ables considered in the analyses included recipient
age, sex, performance score, diagnosis, and disease stage
at transplantation. Transplantation- related variables
included donor age, donor–recipient sex match, donor–
recipient cytomegalovirus serology, donor parity,
preparative therapy (radiation-containing vs non–radia-
tion-containing), GVHD prophylaxis (T cell depletion
vs no T cell depletion), HLA matching (8 allele match
vs 7/8 match, including single allele mismatch but anti-
gen match and single antigen mismatch), and year of
transplantation (1990-1998 vs 1999-2003).
RESULTS
Acute GVHD
The cumulative incidence of grade II-IV aGVHD
was 45% (95% confidence interval [CI] 5 42% to
49%), and that of grade III-IV aGVHD was 27%,
Table 2. Multivariate Analysis for Relapse in Children
Diagnosed with AMLWho Underwent URD BMT (n 5 156)
Variable n OR (95% CI) P value
HLA matching
Matched 69 1.00*
7/8 matched 87 0.63 (0.26 to 1.55) .36
Other significant covariates
Grade III-IV aGVHD
No 89 1.00*
Yes 67 0.58 (0.22 to 1.58) .26
Disease stage <.0001
Early 33 1.00*
Intermediate 69 0.90 (0.23 to 3.54) .88
Advanced 54 12.59 (3.09 to 51.32) .0004
Recipient age category .0059
< 5 years 46 1.00*
6 to 10 years 32 0.40 (0.13 to 1.28) .12
11 to 15 years 47 0.12 (0.04 to 0.39) .0005
16 to 17.9 years 31 0.12 (0.02 to 0.65) .014
Transplantation era
1999-2003 64 1.00*
1990-1998 92 0.14 (0.13 to 0.73) .0075
AGVHD III-IV is treated as a time-dependent variable.
*Reference group.
Table 3. Multivariate Analysis for Relapse in Children
Diagnosed with ALLWho Underwent URD BMT (n 5 311)
Variable n OR (95% CI) P Value
HLA matching
Matched 147 1.00*
7/8 matched 164 0.72 (0.37 to 1.43) .45
Grade III-IV aGVHD
No 168 1.00*
Yes 143 0.34 (0.13 to 0.86) .0052
Disease stage .0012
Early 62 1.00*
Intermediate 214 1.96 (0.74 to 5.17) .17
Advanced 35 12.77 (3.83 to 42.55) < .0001
Recipient age category .05
< 5 years 67 1.00*
6 to 10 years 114 0.38 (0.17 to 0.89) .025
11 to 15 years 75 0.22 (0.07 to 0.66) .0069
16 to 17.9 years 55 0.31 (0.11 to 0.87) .025
Transplantation era
1999-2003 113 1.00*
1990-1998 198 0.51 (0.26 to 1.01) .054
*Reference group.
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Multivariate analysis found similar risk factors for
grade II-IV and grade III-IV aGVHD. As expected,
T cell–replete grafts were associated with a signifi-
cantly increased risk of aGVHD compared with
T cell–depleted grafts (odds ratio [OR] 5 3.12; 95%
CI 5 2.02 to 4.83; P\ .0001). In addition, transplan-
tation in 1990-1998 was associated with significantly
increased risk of aGVHD compared with transplanta-
tion in 1999-2003 (OR5 1.93; 95%CI5 1.27 to 2.91;
P 5 .002). Notably, HLA mismatch at a single locus
did not increase risk of GVHD (OR 5 1.00; 95%
CI 5 0.68 to 1.46; P 5 .98), and age and diagnosis
also did not significantly modify the risk.
Chronic GVHD
The cumulative incidence of cGVHD was 35%
(95%CI5 31% to 38%) 3 years after BMT.Multivari-
ate analysis of risk factors for cGVHD revealed only
a modest, non–statistically significant increase in the
risk of cGVHD associated with a parous female donor
(OR 5 1.45; 95% CI 5 0.92 to 2.29; P 5 .11), and no
effect on risk associated with HLA mismatch (OR 5
1.19; 95%CI5 0.78 to1.79;P5 .41) orTcell depletion.
Relapse
The cumulative incidence of relapse was 26%
(95% CI5 22% to 29%) at 3 years. Multivariate anal-
ysis of risk factors for relapse was conducted for the
entire group and separately for those children with
AML and with ALL, because we hypothesized that
risk factors might differ in these 2 categories. The
risk of relapse was significantly lower in children
with MDS compared with those with acute leukemias,
with markedly increased risk in those children with the
most advanced disease (OR5 15.37, 95% CI5 6.1 to
38.7; P\ .0001). The risk of relapse declinedmarkedly
with increasing recipient age (OR5 0.23 for recipients
age 16 to 18 years compared with a reference group of
children under age 5 years; 95%CI5 0.10 to 0.54; P5
.0004). The risk of relapse was reduced in recipients of
marrow from parous female donors (OR 5 0.43; 95%
CI 5 0.23 to 0.83; P 5 .01), perhaps reflecting the
modest increase in cGVHD in these children, and
was not increased in recipients of T cell–depleted mar-
row. A perhaps surprising observation was a decreased
risk of relapse in children who underwent transplanta-
tion in 1990-1998 compared with those who did so in
1999-2003 (OR 5 0.47, 95% CI 5 0.28 to 0.78;
P 5 .004).
Multivariate analysis of risk factors for relapse
restricted to children with AML (n 5 156) demon-
strated a nonsignificant reduction in incidence of
relapse (OR 5 0.58 comparing relapse incidence in
children with GVHD grade III-IV with those without
GVHD; 95% CI 5 0.22 to 1.58; P 5 .26) (Table 2).But the risk of relapse was significantly higher in chil-
dren who underwent BMT in 1999-2003, in children
under age 5 years, and in children with advanced dis-
ease, as was seen in the group overall. In contrast,
the occurrence of aGVHD significantly reduced the
risk of relapse in children with ALL (OR 5 0.34 com-
paring relapse incidence in children with aGVHD
grade II-IV with those without aGVHD; 95% CI 5
0.13 to 0.86; P5 .0052) (Table 3). Similar to the find-
ings in children with AML, children over age 5 years
with ALL and less advanced disease had a reduced
risk of relapse. Although the risk of relapse was
increased in children who underwent BMT in 1999-
2003, this increase was of only marginal statistical
significance in the children with ALL.
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Figure 2. TRM according to aGVHD grade in children with leukemia
undergoing URD BMT.
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Fifty six percent (95% CI 5 52% to 59%) of chil-
dren were surviving at 1 year after BMT, and 43%
(95% CI 5 39% to 47%) were surviving at 5 years.
The occurrence of aGVHD had a significant effect
on survival (Figure 1). Survival was notably reduced
in children with grade III-IV GVHD, but not in those
with grade II GVHD. In a multivariate model of risk
factors for mortality, the occurrence of aGVHD was
associated with an almost doubled risk of death (rela-
tive risk 5 1.96; 95% CI 51.46 to 2.29; P\ .0001);
however, survival was not improved by T cell deple-
tion, despite a significant reduction in GVHD.
Mortality was increased in older children, as a conse-
quence of increased TRM (OR 5 1.72 in children
age 16 to 18 years compared with those age\5 years;
95% CI 5 1.11 to 2.67; P 5 .016). Children receiving
marrow mismatched at a single locus had significantly
reduced survival, despite the absence of a significant
effect on GVHD (OR 1.42; 95% CI 5 1.05 to 1.92;
P 5 .02). TRM was significantly increased in children
with grade III-IV GVHD, but not in children with
grade II GVHD (Figure 2). TRM was higher in the
children who underwent BMT in 1990-1998 com-
pared with those who did so in 1999-2003 (OR 5
1.61; 95% CI 5 1.03 to 2.51; P 5 .027).
Figure 3 illustrates the overall effect of transplanta-
tion era and GVHD. Survival was reduced in the
children who developed GVHD, regardless of trans-
plantation era. The increased risk of relapse in the
children who underwent BMT in 1999-2003 led to
slightly lower disease-free survival in these children
whether or not they developed GVHD, but the differ-
ence is not statistically significant (P 5 .81).DISCUSSION
Children constitute an important subset of patients
receiving BMT. Despite differences in diagnoses,
organ function, and immune reconstitution capability,0.0
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Figure 1. Probability of overall survival by aGVHD grade in children
with leukemia undergoing URD BMT.children and adults often are considered together in
studies of GVHD, and reports of the effect of age on
the incidence of GVHD have been inconsistent
[4,5,7,8,19-25], with a lower risk of GVHD in younger
patients described in some reports but not in others.
The small number of children undergoing BMT rela-
tive to adults has limited studies focused specifically on
children.We examined a large database to examine the
incidence, risk factors, and outcome of GVHD in chil-
dren to determine whether children with GVHD have
similar risk factors and outcomes as adults, and to
examine temporal trends in outcome of URD trans-
plantation in children.
Our analysis found that T cell depletion for
GVHD prophylaxis significantly reduced the risk of
GVHD, as might have been expected. In addition,
year of transplantation was a significant risk factor,
with a lower risk of GVHD seen in the more recent
transplantations. Perhaps unexpectedly, the risk of
GVHD was not increased by an allele or antigen mis-
match at a single HLA locus, in contrast to findings in
adult studies [20,21,23,24]. This may indicate a greater
tolerance of modest degrees of HLA disparity in
pediatric transplant recipients compared with adults,
or greater success of GVHD prophylaxis in control-
ling alloreactivity. It should be noted, however, that
survival was reduced in recipients of allele- or
antigen-mismatched bone marrow, perhaps indicating
inferior immune reconstitution in this circumstance,
despite the lack of a measurable excess of GVHD.
Our analysis of risk factors for cGVHD failed to
identify any important risk factors besides a marginal
increase in risk with multiparous female donors, as
described by others [26-33]. Of note, HLA mismatch
did not increase the risk of cGVHD, in agreement
with our findings in aGVHD, and the risk was not
decreased by T cell depletion of the graft. It should
be noted that the overall incidence of cGVHDwas sig-
nificant, with approximately 1/3 of children affected,
including even the youngest children; thus, efforts
should be made to provide effective treatment for
cGVHD in all age groups.
Figure 3. Disease-free survival in 1990-1998 and 1999-2003, adjusted for the occurrence of GVHD (P 5 .81).
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children with ALL who developed grade III-IV
aGVHD. This finding is perhaps surprising, because
the clinical experience of quite limited responses to
donor lymphocyte infusions in ALL suggest that any
graft-versus-leukemia (GVL) effect in ALL might be
modest reviewed in [34]. But data from previous non-
pediatric registry studies of sibling and URD BMT
support the finding of a reduced relapse rate in patients
with ALL who develop GVHD [35,36]. Horowitz
et al. [35] analyzed 2254 sibling donor transplantations
performed in children and adults with early-stage
leukemia (ALL or AML in CR1 and CML in CP1)
reported to the IBMTR. This study, which included
439 cases of ALL, found an almost 3-fold reduced
risk of relapse associated with aGVHD, but no effect
in cGVHD. Similarly, a low relapse rate, attributed
toGVL, was reported in a study of 127 adults receiving
URD BMT for high-risk ALL, facilitated by the
NMDP [36].
It is perhaps equally surprising that reduced re-
lapse was not seen in the children with AML; the rea-
son for this is not clear. It is possible that competing
mortality from severe GVHD obscured any benefit
from GVHD, or that the small sample size rendered
a biologically meaningful effect statistically insignifi-
cant. Future studies will readdress this question as ad-
ditional transplantation data are accrued.
Ourdatademonstrate a significant effect of grade III-
IV aGVHDonmortality, with an almost doubled risk of
death in childrenwith aGVHD,demonstrating the inad-
equacy of current treatments for aGVHD. In contrast,
grade II GVHD had only a minor effect on survival.
Performance of randomized controlled trials to optimize
the treatment of aGVHDis an essential step toward im-
proving survival in children receiving URD BMT.
Our analysis identified some striking temporal
changes in the outcome of URD BMT in children
with leukemia. The risk of aGVHD was reduced in
transplantations performed in 1999-2003 comparedwith those performed before 1999, even with inclusion
of T cell depletion and HLAmatching in the multivari-
ate model. These data may indicate greater recent suc-
cess in optimizing the use of calcineurin inhibitors
and/or methotrexate as GVHDprophylaxis. In contrast
to this improvement in outcome, the risk of relapse was
increased in the children undergoing transplantation in
1999-2003, with this increase most notable in children
with AML. This may reflect the use of increasingly in-
tensechemotherapy in theprimary treatmentof children
with AML. Of note, 35% of the children with AML
underwent transplantation with advanced disease, com-
pared with 11% of the children with ALL. In addition,
criteria for selecting children with leukemia for trans-
plantation change frequently, based on, for example, im-
proved identification of genetic characteristics that
affect the risk of relapse and increased effectiveness of
chemotherapy. Notably, the era of transplantation
was not a significant risk factor for overall survival, per-
haps indicating that recent reductions in GVHD are
counterbalanced by the increase in relapse, illustrating
the dynamic nature of leukemia patient populations as
chemotherapy outcomes continue to evolve.
The present study is a registry analysis and so is
limited by the heterogeneity of treatment regimens
and clinical practices at different institutions. A
strength of the study is the size of the population, al-
lowing analyses of subsets that could not be examined
in single institution studies.
In summary, this study is the largest single analysis
of GVHD in URD BMT in children reported to date.
We have identified important temporal changes in clin-
ical outcomes that will merit continued observation as
chemotherapy and transplantation strategies continue
to improve. In addition, we have shown a significant
effect of GVHD in reducing relapse in children with
ALL, but not in those with AML. But overall, aGVHD
had a significant negative effect on survival, demonstrat-
ing the need for further improvements in both GVHD
prophylaxis and aGVHD treatment.
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